In Vivo Evaluation of Recombinantly Expressing M-Cell-Targeting Co1 Peptide Fused with VP1 of Enterovirus A71 Capsid

[1]  F. Tonello,et al.  Nucleolin: a cell portal for viruses, bacteria, and toxins , 2022, Cellular and Molecular Life Sciences.

[2]  Huyen-Trang Vu,et al.  Recombinant Human SCARB2 Expressed in Escherichia coli and its Potential in Enterovirus 71 Blockage , 2021, Iranian journal of science and technology. Transaction A, Science.

[3]  S. Koike,et al.  Newly emerged enterovirus-A71 C4 sublineage may be more virulent than B5 in the 2015–2016 hand-foot-and-mouth disease outbreak in northern Vietnam , 2020, Scientific Reports.

[4]  S. Gau,et al.  Enterovirus A71 neurologic complications and long-term sequelae , 2019, Journal of Biomedical Science.

[5]  R. New,et al.  Formulation technologies for oral vaccines , 2019, Clinical and experimental immunology.

[6]  N. An,et al.  Cloning, expression and purification of m-cell specific binding peptide (CO1) fused with GFP , 2018 .

[7]  H. V. van Doorn,et al.  Evolution and Spatiotemporal Dynamics of Enterovirus A71 Subgenogroups in Vietnam , 2017, The Journal of infectious diseases.

[8]  N. Peppas,et al.  Current state and challenges in developing oral vaccines. , 2017, Advanced drug delivery reviews.

[9]  Sun-Young Chang,et al.  Enterovirus 71 infection and vaccines , 2017, Clinical and experimental vaccine research.

[10]  G. Patel,et al.  Induction of mucosal immunity through systemic immunization: Phantom or reality? , 2016, Human vaccines & immunotherapeutics.

[11]  Pei-Yin Lim,et al.  Neutralizing antibodies can initiate genome release from human enterovirus 71 , 2014, Proceedings of the National Academy of Sciences.

[12]  Kyung‐Yeol Lee,et al.  Application of an M-cell-targeting ligand for oral vaccination induces efficient systemic and mucosal immune responses against a viral antigen. , 2013, International immunology.

[13]  Y. Jang,et al.  Targeted Delivery of VP1 Antigen of Foot-and-mouth Disease Virus to M Cells Enhances the Antigen-specific Systemic and Mucosal Immune Response , 2013, Immune Network.

[14]  H. Kiyono,et al.  M cells expressing the complement C5a receptor are efficient targets for mucosal vaccine delivery , 2011, European journal of immunology.

[15]  Kyung‐Yeol Lee,et al.  The M Cell-Targeting Ligand Promotes Antigen Delivery and Induces Antigen-Specific Immune Responses in Mucosal Vaccination , 2010, The Journal of Immunology.

[16]  Jun Han,et al.  Long persistence of EV71 specific nucleotides in respiratory and feces samples of the patients with Hand-Foot-Mouth Disease after recovery , 2010, BMC infectious diseases.

[17]  F. Avilés,et al.  Inclusion bodies: specificity in their aggregation process and amyloid-like structure. , 2008, Biochimica et biophysica acta.

[18]  B. Chiang,et al.  Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. , 2006, Vaccine.